Member Info for Mafuta

So Deucravacitinib and Beprocitinib are rat poison compared to our 1801 ... Form an overly line ... LH&K from Tunisia

As icecool quite rightly points out they are publicly saying we're for sale if the price is right. The sale may include some or all the assets but no formal offer has been made (yet). The section 8 paperwork is all about compliance with the take over panel. Interesting times for TRX. LH&K Mafuta

TRX has issued a section 8 form so they are now in an offer period. Here's what my broker issued [FWIW]:

"Tissue Regenix Group Plc has announced details of a strategic review and launch of a formal sales process. This means that the company will review all options available including a possible sale of the company, and/or its assets. The company is now considered to be in an offer period, however there can be no certainty that an official offer will be made."

Make of it what you will ... as the Cheshire cat said "Curious and curiouser" ... LH&K Mafuta

Thanks for the link Richard ... Glad it's not only me that's somewhat nonplussed over the RNS wording 🤔

Sorry gin thought you meant yesterday's RNS .... Try this link https://code.thetakeoverpanel.org.uk/tp/rules/rule-8/rule-8.html

Mafuta

I think what they are saying is they are not denying or confirming talks have taken place but they are open to offers ... It's a rather vague statement but that's my take on it ... LH&K Mafuta

Must be honest I actually missed the RNS yesterday 😲 Don't know what to make of the rather vague announcement ... But it certainly looks like they setting their stall up ... Time will tell. LH&K Mafuta

Oh the good old MM codes ;0)

I however found this line encouraging:

"No clinically significant effects on any component of blood, which have been affected by earlier generation JAK inhibitors, were observed. The observed favourable safety and pharmacokinetic profiles may give SDC-1801 significant advantage over competitors."

LH&K Mafuta

A good positive step 👍

The RNS stated that the "net funds will be utilised by the Company to further develop its lead candidate SDC-1801, culminating in longer-term toxicology studies required to support Phase 2 clinical trials in patients." ... I get the distinct impression that the intent is to partner up BEFORE phase II ... What the funding allows in effect is for SAR to bat off the low ball offers ... literally saying "if you haven't got deep pockets, we'll go to phase II then you will have to pay more." ... just my opinion, take it or leave it ... LH&K Mafuta

This is the interesting bit: "Based on the (now available) unblinded data, management has reiterated SDC-1801’s robust safety profile (adverse events similar to placebo and no clinically significant impact on any blood component), an important consideration given the off-target toxicities associated with previous generation JAK inhibitors. Unblinded data from the multiple ascending dose cohorts also demonstrated dose-dependent reductions in three biomarkers of JAK1 and TYK2 activity, which are key mediators of major inflammatory pathways. While several TYK2 inhibitors are currently under development (Bristol Myers Squibb’s Sotyktu was approved by the FDA in 2022), Sareum asserts that the dual inhibition property of SDC-1801 potentially offers greater therapeutic potential. We will present a more detailed analysis of Sareum’s ongoing programmes following the release of the full-year results later this month." LH&K Mafuta

The traders and shorters on this BB are so transparent ... they could be called Darlington Crystal ... LH&K Mafuta

Good to see SAR lining all their ducks up ... LH&K Mafuta

Great results well done Mo and team

Excellent results well done team trx

Today's announcement of the collaboration with the Moffitt Cancer Center marks a major inflection point in the Company's development, and delivery of our proprietary CIZ1B biomarker test to market, by enabling patients in a major cancer clinic with suspicious lung nodules to be tested for the presence of the biomarker. Having transitioned from the development phase into full commercial manufacture of the Company's CIZ1B monoclonal antibody and in establishing a guaranteed royalty bearing licence with our US partners Cizzle BIO, we are now able to forge new links with doctors, hospitals and major cancer clinics, initially in North America and then to make the test available elsewhere in the world.

We are pleased to extend the patent protection for SDC-1801 on the back of the encouraging data from our Phase 1a trial, indicating our inhibitor could confer significant advantages over other TYK2/JAK1 kinase inhibitors. We remain motivated in progressing SDC-1801 through clinical development to develop new therapeutics for autoimmune diseases and cancers."

Oracle ... It certainly takes a lot to get a scientist excited ... I should know ... I worked with lots of them at one time ...LH&K Mafuta

Mark I would say it's not just a chance but very likely ... LH&K Mafuta